A carregar...
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new op...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3063116/ https://ncbi.nlm.nih.gov/pubmed/21448449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S13029 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|